Respiratory Morbidities of Prematurity (RMP) Clinical Trial
Official title:
Open-label Study to Assess the Safety, Tolerability, Feasibility, and Pharmacokinetics of Inhaled RVT-1601 in Preterm Infants at High-risk for Long-term Respiratory Morbidities
| Verified date | June 2020 |
| Source | Respivant Sciences Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Preterm birth predisposes infants to greater risk for respiratory morbidities and the need
for pulmonary care compared to term infants both in the short-term and long-term. In the
short-term, preterm birth is a high risk factor for development of bronchopulmonary dysplasia
(BPD), the second most common chronic pediatric respiratory disease after asthma. In the
long-term, following discharge from the neonatal intensive care unit (NICU) and the hospital,
preterm birth carries a high risk for respiratory morbidities (e.g., wheezing, cough, doctor
visits, and hospitalizations for respiratory infections) and resource use, which in turn
predisposes infants to the development of lung diseases in childhood and adulthood, including
airway hyperresponsiveness, asthma, and chronic obstructive pulmonary disease (COPD). There
is a significant unmet need for safe and efficacious approaches in the prevention and
treatment of respiratory morbidities of prematurity.
The study will be conducted in the neonatal intensive care unit (NICU) in preterm infants to
determine safety, tolerability and lung delivery performance of RVT-1601, a new inhalation
formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer/face
mask.
| Status | Completed |
| Enrollment | 8 |
| Est. completion date | May 29, 2020 |
| Est. primary completion date | May 29, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 32 Months to 35 Months |
| Eligibility |
Inclusion Criteria: - Preterm infants between 32 weeks 0 days and 34 weeks 6 days of PMA - Born between 24 weeks 0 days and 29 weeks 6 days of estimated GA - Requiring minimal or no respiratory support (i.e., supplemental oxygen with <2 liters per minute of nasal cannula flow acceptable) - Body weight appropriate for gestational age - Written informed consent obtained from at least one of the parents or legal guardians Exclusion Criteria: - Requiring invasive or noninvasive respiratory support (e.g., mechanical ventilation, CPAP) - Clinically unstable (i.e. unable to maintain SpO2 between 90-95 % , escalating respiratory support in the past 24 hours) - Major congenital anomaly (chromosomal, renal, cardiac, hepatic, neurologic or pulmonary malformations) - Significant cardiac disorder (i.e., pulmonary hypertension) - History of major surgical procedure - Any condition that would preclude receiving study drug or performing any study-related procedures - Participation in any other investigational drug study - History of hypersensitivity or intolerance to cromolyn sodium |
| Country | Name | City | State |
|---|---|---|---|
| United States | Sharp Mary Birch Hospital for Women & Newborns | San Diego | California |
| Lead Sponsor | Collaborator |
|---|---|
| Respivant Sciences GmbH | Respivant Sciences Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in heart rate | Assessment of heart rate (beats/min) | Pre-dose and 15 minutes post-dose | |
| Primary | Change in blood pressure | Assessment of systolic and diastolic blood pressure (mmHg) | Pre-dose and 15 minutes post-dose | |
| Primary | Change in oxygenation | Assessment of peripheral capillary oxygen saturation (SpO2) | Pre-dose and 15 minutes post-dose | |
| Secondary | Peak plasma concentration (Cmax) | Assessment of peak plasma concentration of RVT-1601 | 30 minutes post-dose | |
| Secondary | Total urine excretion | Assessment of total urine content of RVT-1601 | 8 hours post-dose |